Kimberly Ha’s Post

View profile for Kimberly Ha, graphic

Founder & CEO at KKH Advisors

Excited to announce that FaunaBio and Eli Lilly and Company have announced a strategic collaboration to discover novel #obesity targets using its #Convergence AI platform in a deal worth up to $494M. 🚀🚀🚀 Fauna's Convergence™ AI platform analyzes data collected from the protective adaptations of hibernation biology (and other extreme adaptations) to identify drug targets for humans. Fauna identifies the best genes to target for efficacy in diseases with high unmet need and can identify genes to target within a broad range of treatment modalities. "We are very excited to enter into this collaboration with Lilly, which showcases the power of our Convergence™ AI platform to rapidly identify novel targets for complex disease areas of high unmet need," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio. "Lilly is a leader in obesity treatment, and our approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development." Read the full release: 👇👇👇 https://lnkd.in/eXKDEKze

  • No alternative text description for this image
David Li

CEO, co-founder at Meliora Therapeutics

9mo

congrats Ashley Zehnder!

Cameron Pye

Co-Founder Unnatural Products Inc.

9mo

congrats Ashley Zehnder and Fauna team!

See more comments

To view or add a comment, sign in

Explore topics